Rituximab-Induced Psoriasis in a Patient with Granulomatosis with Polyangitis Treated with Adalimumab.
Hana S AlahmariNasser Y AlhowaishMohammed A OmairPublished in: Case reports in rheumatology (2019)
Rituximab (RTX) is a chimeric B-cell-depleting monoclonal antibody against CD-20 positive cells that has been approved for the induction and maintenance of granulomatosis with polyangiitis (GPA). Reports have identified RTX to cause drug-related psoriasis. Many theories of underlying pathways have been proposed. However, further workup around the mechanism and treatment is required. Here, we present a 38-year-old woman known to have GPA that developed drug-related psoriasis that was successfully treated with treatment discontinuation and starting adalimumab along with a literature review.
Keyphrases
- monoclonal antibody
- rheumatoid arthritis
- case report
- diffuse large b cell lymphoma
- drug induced
- induced apoptosis
- juvenile idiopathic arthritis
- emergency department
- adverse drug
- mesenchymal stem cells
- cell therapy
- cell proliferation
- systemic lupus erythematosus
- high glucose
- hodgkin lymphoma
- cell death
- ulcerative colitis
- stress induced